首页 | 本学科首页   官方微博 | 高级检索  
检索        

丁苯酞+依达拉奉治疗进展性脑梗死的临床效果
引用本文:司铁彬.丁苯酞+依达拉奉治疗进展性脑梗死的临床效果[J].中国现代药物应用,2022(3).
作者姓名:司铁彬
作者单位:凌源市中心医院神经内科
摘    要:目的探究丁苯酞+依达拉奉治疗进展性脑梗死(PCI)的临床效果。方法102例PCI患者,以计算机抽号方式随机分为B组和A组,各51例。B组采用依达拉奉治疗,A组采用丁苯酞+依达拉奉联合治疗。比较两组临床效果、用药不良反应发生率、血液流变学指标、治疗前及治疗后1、2周的美国国立卫生研究院卒中量表(NIHSS)评分。结果A组治疗总有效率90.20%高于B组的68.63%,差异有统计学意义(P<0.05)。A组的用药不良反应发生率9.80%(5/51)与B组的7.84%(4/51)比较,差异无统计学意义(P>0.05)。A组患者的纤维蛋白原、全血粘度、血小板聚集率分别为(2.72±1.08)g/L、(1.02±0.02)mPa·s、(52.33±7.54)%,均低于B组的(3.35±1.11)g/L、(1.18±0.08)mPa·s、(63.65±6.67)%,差异有统计学意义(P<0.05)。治疗后1、2周,A组NIHSS评分均低于B组,差异有统计学意义(P<0.05)。结论在PCI患者治疗中,采用丁苯酞+依达拉奉联合用药方案的临床效果显著,能减少患者神经功能损伤,并改善血液流变学,促进康复,且用药不良反应少,安全性高,值得在临床上推广应用。

关 键 词:进展性脑梗死  丁苯酞  依达拉奉  联合用药  临床效果

The clinical effect of butylphthalide combined with edaravone in the treatment of progressive cerebral infarction
SI Tie-bin.The clinical effect of butylphthalide combined with edaravone in the treatment of progressive cerebral infarction[J].Chinese Journal of Modern Drug Application,2022(3).
Authors:SI Tie-bin
Institution:(Department of Neurology,Lingyuan Central Hospital,Lingyuan 122500,China)
Abstract:Objective To investigate the clinical effect of butylphthalide combined with edaravone in the treatment of progressive cerebral infarction(PCI).Methods A total of 102 PCI patients were randomly divided into group B and group A,with 51 cases in each group.Patients in group B were treated with edaravone,patients in group A were treated with butylphthalide and edaravone.The clinical effects,incidence of adverse drug reactions,hemorheological indexes,National Institutes of Health stroke scale(NIHSS)scores before treatment and 1 and 2 weeks after treatment were compared between the two groups.Results The total effective rate of treatment 90.20%in group A was higher than 68.63%in group B,and the difference was statistically significant(P<0.05).The incidence of adverse drug reactions in group A was 9.80%(5/51),which was not statistically significant compared with 7.84%(4/51)in group B(P>0.05).The fibrinogen,whole blood viscosity,and platelet aggregation rate of group A were(2.72±1.08)g/L,(1.02±0.02)mPa·s,and(52.33±7.54)%,which were lower than(3.35±1.11)g/L,(1.18±0.08)mPa·s,and(63.65±6.67)%of group B,and the difference was statistically significant(P<0.05).1 and 2 weeks after treatment,the NIHSS scores of group A were lower than those of group B,and the difference was statistically significant(P<0.05).Conclusion Butylphthalide combined with edaravone has significant clinical effect on patients with PCI,which can reduce the neurological damage,improve hemorheological indexes,greatly promote rehabilitation,and has less adverse reactions and high safety,which is worthy of clinical promotion and application.
Keywords:Progressive cerebral infarction  Butylphthalide  Edaravone  Combination therapy  Clinical effect
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号